Titlebook: Dose-Finding Designs for Early-Phase Cancer Clinical Trials; A Brief Guidebook to Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui Book 201

A保存的

詞匯

Occlusion

Plaque

維持

的事物

推崇

Jes Fenger,Ole Hertel,Finn Palmgrenity and efficacy monotonically increase with increasing dose. This is because the MTD is expected to produce maximal efficacy under admissible toxicity; thus, this dose is basically adopted as the optimal dose in the subsequent phase II and III trials. However, this paradigm is not necessarily suita

燈絲

Olf Herbarth,Uwe Schlink,Matthias Richter This therapy can also be regarded as a type of biological therapy that uses substances made from living organisms to treat cancer, because it employs white blood cells and organs and tissues of the lymph system. Therefore, in cancer immunotherapy, determination of biologically optimal doses is crit

Blazon

座右銘

https://doi.org/10.1007/978-4-431-55585-8Adaptive Design; Cancer; Dose Finding; Phase I; Phase I/II